Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Pipeline Review, H2 2016’, provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted pipeline therapeutics.

The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)

The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects

The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

Amorepacific Corporation

AnaBios Corporation

Centrexion Therapeutics Corp

Daewoong Pharmaceutical Co., Ltd.

DoNatur GmbH

Flex Pharma, Inc.

Grunenthal GmbH

Kyowa Hakko Kirin Co., Ltd.

Medifron DBT Co., Ltd.

Neurim Pharmaceuticals Ltd

PharmEste

Pila Pharma AB

Sylentis S.A.U.

Toray Industries, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) Overview 9

Therapeutics Development 10

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Stage of Development 10

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Therapy Area 11

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Indication 12

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Companies 16

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Universities/Institutes 19

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment 21

Assessment by Monotherapy/Combination Products 21

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development 28

Amgen Inc. 28

Amorepacific Corporation 29

AnaBios Corporation 30

Centrexion Therapeutics Corp 31

Daewoong Pharmaceutical Co., Ltd. 32

DoNatur GmbH 33

Flex Pharma, Inc. 34

Grunenthal GmbH 35

Kyowa Hakko Kirin Co., Ltd. 36

Medifron DBT Co., Ltd. 37

Neurim Pharmaceuticals Ltd 38

PharmEste 39

Pila Pharma AB 40

Sylentis S.A.U. 41

Toray Industries, Inc. 42

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles 43

AMG-986 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BK-1119 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

capsaicin - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

capsaicin - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CMX-020 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

DWP-05195 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

FLX-787 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

K-685 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

MCS-18 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

MDR-16523 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

MDR-652 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

NEO-6860 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

PAC-14028 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Peptides to Target TRPV1 for Pain and Itch - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

PHE-575 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

piromelatine - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

QX-314 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

resiniferatoxin - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecule to Block TRPV1 for Pain - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecule to Block TRPV1 for Pain - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecules to Block TRPA1 and TRPV1 for Pain - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Small Molecules to Block TRPA1 and TRPV1 for Pain and Inflammation - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecules to Block TRPV1 for Oncology - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

SYL-1001 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

XEND-0501 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

zucapsaicin - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Projects 84

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products 92

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Featured News & Press Releases 93

Oct 13, 2016: Flex Pharma Provides FLX-787 Nocturnal Leg Cramp Regulatory and Clinical Update 93

Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimer’s Disease 94

Sep 13, 2016: Flex Pharma Initiates Phase 2 Efficacy Study in Amyotrophic Lateral Sclerosis 95

Jul 26, 2016: Flex Pharma Completes Enrollment of Human Proof-of Concept Efficacy Study in Nocturnal Leg Cramps 95

Jun 15, 2016: Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis 96

May 25, 2016: Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps 97

Apr 19, 2016: Flex Pharma’s Positive Human NLC Study Selected for Presentation at AAN Annual Meeting 97

Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 99

Mar 14, 2016: Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting 99

Feb 02, 2016: Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study 100

Jan 26, 2016: NEOMED to Initiate Its First Phase II Clinical Trial in Canada 101

Jan 06, 2016: Enrollment Completed in Flex Pharma’s Exploratory Human Nocturnal Leg Cramp Study 101

Nov 19, 2015: Astellas Announces Results from the First Head to Head Study Comparing QUTENZA (Capsaicin 8% Patch) with Current Standard of Care in Patients with Peripheral Neuropathic Pain 102

Nov 10, 2015: Flex Pharma Announces FLX-787 as Clinical Drug Candidate 103

Oct 20, 2015: Flex Pharma Demonstrates Single Agent Efficacy and Dose Response in Reducing Human Muscle Cramps 104

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Assessment by Monotherapy/Combination Products, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Pipeline by Amgen Inc., H2 2016 28

Pipeline by Amorepacific Corporation, H2 2016 29

Pipeline by AnaBios Corporation, H2 2016 30

Pipeline by Centrexion Therapeutics Corp, H2 2016 31

Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 32

Pipeline by DoNatur GmbH, H2 2016 33

Pipeline by Flex Pharma, Inc., H2 2016 34

Pipeline by Grunenthal GmbH, H2 2016 35

Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 36

Pipeline by Medifron DBT Co., Ltd., H2 2016 37

Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 38

Pipeline by PharmEste, H2 2016 39

Pipeline by Pila Pharma AB, H2 2016 40

Pipeline by Sylentis S.A.U., H2 2016 41

Pipeline by Toray Industries, Inc., H2 2016 42

Dormant Projects, H2 2016 84

Dormant Projects (Contd..1), H2 2016 85

Dormant Projects (Contd..2), H2 2016 86

Dormant Projects (Contd..3), H2 2016 87

Dormant Projects (Contd..4), H2 2016 88

Dormant Projects (Contd..5), H2 2016 89

Dormant Projects (Contd..6), H2 2016 90

Dormant Projects (Contd..7), H2 2016 91

Discontinued Products, H2 2016 92

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports